Loading...
People with attention-deficit/hyperactivity disorder (ADHD) can have >300 mutations in glutamate network genes, including 79 mutations found to be 10-fold more common in individuals with ADHD. Now, researchers have reported findings from a manufacturer-supported, phase I study of pharmacokinetics, safety, and efficacy of a non-FDA-approved drug, fasoracetam, which targets the metabotropic glutamate receptor 5. Fasoracetam has been studied for dementia because of its cholinergic activity; it does not have dopaminergic, serotonergic, or adrenergic actions.
The 30 medication-free patients with ADHD and glutamate gene mutations (mean age, 14 years; age range, 12–17; 20 boys) underwent a pharmacokinetic study, followed by a single-blind drug-esca…